Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-R01 in postoperative pancreatic cancer
NCT06888674Phase 2Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of iNeo-Vac-R01 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhejiang University. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
iNeo-Vac-R01
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06888674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888674.